{"article_title": "Federal Circuit tries to explain \u2018unclear\u2019 biologics law", "article_keywords": ["recent", "unclear", "treats", "federal", "explain", "soon", "biologics", "practical", "start", "tries", "selling", "sandoz", "result", "circuit", "v", "law", "ruling"], "article_url": "http://www.insidecounsel.com/2015/07/24/federal-circuit-tries-to-explain-unclear-biologics", "article_text": "A recent ruling by judges from the U.S. Court of Appeals for the Federal Circuit makes it more likely that Sandoz soon may be able to start selling a biosimilar that treats cancer patients.\n\nBut beyond this practical result, there are many more far-reaching consequences from the ruling in Amgen v. Sandoz.", "article_metadata": {"sailthru.author": "Ed Silverstein", "description": "A recent ruling by judges from the U.S. Court of Appeals for the Federal Circuit makes it more likely that Sandoz soon may be able to start selling a biosimilar that treats cancer patients.", "og": {"url": "http://www.insidecounsel.com/2015/07/24/federal-circuit-tries-to-explain-unclear-biologics", "image": "http://media.insidecounsel.com/insidecounsel/article/2015/07/23/pharma59.jpg", "type": "website", "description": "A recent ruling by judges from the U.S. Court of Appeals for the Federal Circuit makes it more likely that Sandoz soon may be able to start selling a biosimilar that treats cancer patients.", "title": "Federal Circuit tries to explain \u2018unclear\u2019 biologics law"}, "sailthru.date": "2015-07-24", "sailthru.tags": "insidecounsel, article, 55b10390160ba07a02f96fc4, Inside Insights, Regulatory,Licensing/Transactions,Patents, FDA,Food and Drug Administration,pharmaceuticals,biosimilars,patents,regulatory,licensing/transactions", "keywords": "Regulatory, Patents, Licensing/Transactions, FDA, U.S. Court of Appeals, pharmaceuticals, Food and Drug Administration, Amgen, Alan Lourie, biosimilars, Garrett, health insurance exchanges, Winston Churchill, Levin", "google-site-verification": "taA-AsTDqnL-gUE2YkrQ-AE8bLsQz3HBlhUTtFyJPas", "sniply-options": "block", "sailthru.image.full": "http://media.insidecounsel.com/insidecounsel/article/2015/07/23/pharma59.jpg", "viewport": "width=device-width, minimum-scale=1.0, maximum-scale=1.0, user-scalable=0"}, "_id": "\"57477af36914bd0286fcaf6c\"", "article_summary": "But beyond this practical result, there are many more far-reaching consequences from the ruling in Amgen v. Sandoz.\nA recent ruling by judges from the U.S. Court of Appeals for the Federal Circuit makes it more likely that Sandoz soon may be able to start selling a biosimilar that treats cancer patients."}